ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGERCOR - Multidisciplinary Oncology Cooperative Group
About this trial
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of Colorectal cancer liver metastasis.
Eligibility criteria
Qualifiers
Has signed informed consent form and is willing to comply with all study procedures and availability for the study duration,
Is ≥ 18 years of age,
Has histologically confirmed colorectal adenocarcinoma,
Has resected primary tumor or is eligible to primary tumor and CRLM (in case of synchronous metastases) resection within 6 months prior to study inclusion,
Disqualifiers
Has definitively unresectable CLRM,
Had more than 9 pre-operative cycles of chemotherapy for treatment of metastatic disease planned at inclusion,
Has not resected primary rectal tumor (low and middle),
Has history of another primary cancer within the last 5 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix,
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov